Luxbright AB (SE:LXB)
:LXB
Want to see SE:LXB full AI Analyst Report?
Top Page
Luxbright AB
(LXB)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr0.13
▼(-73.75% Downside)
Action:Reiterated
Date:05/30/26
The score is primarily weighed down by weak financial performance—ongoing heavy losses and sustained cash burn—despite a low-debt balance sheet. Technicals add further pressure given the pronounced downtrend and negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and has no dividend yield data.
Positive Factors
Accelerating revenue growth
Revenue acceleration in the last reported periods indicates improving commercial traction and product-market fit. Sustained top-line growth over multiple periods provides a durable runway to scale operations, improve operating leverage, and attract follow-on financing if cash burn is addressed.
Negative Factors
Sustained cash burn
Consistent negative operating cash flow signals the business consumes internal resources to operate and likely needs external capital to sustain growth. Persistent cash burn increases dilution and execution risk over the next several quarters, constraining investment in commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating revenue growth
Revenue acceleration in the last reported periods indicates improving commercial traction and product-market fit. Sustained top-line growth over multiple periods provides a durable runway to scale operations, improve operating leverage, and attract follow-on financing if cash burn is addressed.
Read all positive factors
Luxbright AB (LXB) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr34.10M
Dividend YieldN/A
Average Volume (3M)49.93K
Price to Earnings (P/E)―
Beta (1Y)-0.57
Revenue Growth27.31%
EPS Growth6.31%
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.16
Shares Outstanding260,296,020
10 Day Avg. Volume14,295
30 Day Avg. Volume49,930
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.09
Price to Sales (P/S)4.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr35.75M
Luxbright AB Business Overview & Revenue Model
Company Description
Luxbright AB (publ), a technology-driven enterprise headquartered in Gothenburg, Sweden, specializes in engineering and marketing X-ray tubes, generators, and comprehensive X-ray systems. Established in 2012, the company's primary focus is on prov...
How the Company Makes Money
Publicly available, company-specific detail on Luxbright AB’s current revenue model, revenue streams, customer contracts, pricing, or material partnerships is not available in the information provided, so a factual detailed explanation cannot be g...
Luxbright AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.41M | 9.02M | 854.70K | 811.70K | 729.00K |
| Gross Profit | -21.37M | 8.88M | -2.80M | 189.12K | 1.98M |
| EBITDA | -16.76M | -15.72M | -23.87M | -20.47M | -17.63M |
| Net Income | -19.46M | -17.72M | -25.38M | -21.13M | -18.10M |
Balance Sheet | |||||
| Total Assets | 39.38M | 42.66M | 40.69M | 31.19M | 23.99M |
| Cash, Cash Equivalents and Short-Term Investments | 5.29M | 12.36M | 14.04M | 7.60M | 7.51M |
| Total Debt | 4.56M | 254.19K | 206.02K | 588.34K | 1.10M |
| Total Liabilities | 12.49M | 8.46M | 7.00M | 3.33M | 3.36M |
| Stockholders Equity | 26.89M | 34.20M | 33.69M | 27.86M | 20.63M |
Cash Flow | |||||
| Free Cash Flow | -19.87M | -16.52M | -20.39M | -20.64M | -17.14M |
| Operating Cash Flow | -19.87M | -16.52M | -20.39M | -20.64M | -17.14M |
| Investing Cash Flow | -3.65M | -3.44M | -3.99M | -7.15M | -4.15M |
| Financing Cash Flow | 16.46M | 18.28M | 30.82M | 27.88M | -708.00K |
Luxbright AB Technical Analysis
Negative
0.48
Price Trends
0.15
Negative
0.27
Negative
0.43
Negative
Market Momentum
-0.01
Positive
43.60
Neutral
30.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LXB, the sentiment is Negative. The current price of 0.48 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.15, and above the 200-day MA of 0.43, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.60 is Neutral, neither overbought nor oversold. The STOCH value of 30.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LXB.
Luxbright AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr126.49M | 33.30 | ― | ― | -12.51% | -59.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | kr47.89M | -13.94 | ― | ― | -12.32% | -1156.14% | |
44 Neutral | kr366.07M | -3.08 | -253.54% | ― | 41.17% | 29.20% | |
43 Neutral | kr34.10M | -0.89 | -60.56% | ― | 27.31% | 6.31% | |
43 Neutral | kr111.42M | -3.30 | -61.62% | ― | -29.16% | 44.24% | |
42 Neutral | kr28.24M | -0.46 | -50.21% | ― | ― | -85.81% |
* Healthcare Sector Average
SE:LXB
Luxbright AB
0.13
-0.56
-81.10%
SE:SCIB
SciBase Holding AB
35.80
4.80
15.49%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
3.58
0.88
32.41%
SE:SPEC
SpectraCure AB
0.05
-0.20
-80.40%
SE:SDOS
ScandiDos AB
0.84
-0.56
-40.00%
SE:ARCOMA
Arcoma AB
8.84
-0.56
-5.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.